Psychedelic investors have high expectations for the industry in 2022, as the stagnant financial markets appear poised for a significant run. Mental health awareness is at an all-time high, and with limited treatment options available, the general public is cozying up to the thought of finding help through non-traditional methods.
Supported by numerous ongoing clinical trials, psychedelic therapeutics have emerged as the most promising candidate in the battle against mental disease, and a legislative shift is already underway to make these psychoactive chemicals more accessible to consumers once they are able to go to market.
Josh Bartch, CEO and co-founder of Mydecine Innovations Group joins The Dales Report once again to discuss the company’s active start to the year and offer further insight into the industry’s outlook.
WIth The Dales Report serving as one of the most reputable sources for psychedelic investors today, Bartch leans right into the slums seen across the industry, pointing out that the current trend is not as concerning as some chalk it up to be.
“You had the initial investor that kind of got into psychedelics, without really fundamentally understanding what it takes to operate a biotechnology company and really do end-to-end drug development. It’s a long process. And they kind of had a short-term cannabis mentality. And I think that you’re starting to see a lot of those shorter-term investors kind of take an exit, and a lot of them already have.”
This exodus of inexperienced investors is nothing new when it comes to emerging markets, as hype-driven runs tend to see hopefuls pile on, only to jump ship at the first sign of a decline. Current economic pitfalls are only adding fuel to the fire, creating a false sense of industry instability.
“The new, more sophisticated biotech investor that really understands fundamentally the upside of this industry as a whole and that its a long process. Nothing’s gonna come overnight.”
For those unfamiliar with biotech investing, the string of promising press releases can be somewhat frustrating. They might hint at advances, but procedures and red tape require even the most promising of clinical trial results to undergo a rigorous process before hitting the market.
“The real kind of glory days are definitely ahead of us, and it’s something that we’re working hard to get to… Patience is incredibly important, and you have to weather the storm, the ups and the downs, the ebbs, and the flows. You know, they’re inevitable, but it’s something that it’s all a part of the equation.”
Dales and Bartch further discuss the current situation on Wall Street with an obvious emphasis on psychedelic stocks. Bartch offers his thoughts on the opening quarter of the year and sheds some insight into how he reads and weighs news coming across the PR feed.
The second half of the conversation focuses more specifically on Mydecine and the current trajectory of the brand itself. As mentioned, the brand has seen a steady string of promising press releases, and the company’s co-founder further elaborates on the overall significance of each.
While giant strides are being made in labs across the globe, Bartch still feels that it is going to take a concerted effort to educate the greater public before these psychedelic alternatives become mainstream.
“That takes a large educational curve, data needs to come out that needs to be portrayed in the right way and displayed in the right way and conveyed in the right way to that general medical community.”
“It needs to not be this kind of one-off ‘psychedelic treatments’, it needs to be a part of the actual conversation, right? It needs to be a part of the normal medical complication. And that is a curve and something that’s going to take a long, long time and a lot of money, and a lot of consistent messaging, but it’s definitely going to happen. I’s definitely possible, as long as we have, again, the industry to all needs to tell that consistent message and you can’t have this fragmented messaging where some people want recreational use while others want that. This needs to be consistent if they really want to have this as an adopted and largely accepted treatment.”